Research Summaries

Faculty Member Research Summary
Arpana Agrawal, PhD 1) Genetics of cannabis involvement using epidemiological and genomic methods; 2) G x E models; 3) Comorbidity between substance use and mental illness; 4) Methodology; 5) Genomewide association studies; 6) Meta-analysis
Andrey Anokhin, PhD 1) Genetic variation in human brain function; 2) Neurobehavioral endophenotypes for psychiatric disorders; 3) Causes and consequences of underage substance abuse; 4) Neurocognitive and genetic predictors of successful smoking cessation versus relapse
Andy Belden, PhD 1) Using a developmental psychopathology framework to conduct interdisciplinary and clinically-relevant research that integrates behavioral and neuroscience techniques to advance our understanding of childhood onset mood disorders; 2) Examining the validity of fMRI as a neurobiological assessment tool of cognitive emotion regulation strategies in early childhood
Laura Jean Bierut, MD 1) Genetic studies of psychiatric illnesses; 2) Genetic studies of alcoholism, nicotine and substance dependence; 3) Studies of how policy affects substance use and sexual behaviors in adolescents; 4) Studies linking genetics to smoking cessation outcomes, with and without pharmaceutical treatments
Monica Bishop, MD 1) Eating Disorders
Kevin J. Black, MD 1) neuroimaging; 2) Tourette syndrome; 3) neuropsychiatry of movement disorders; 4) clinical neuropsychiatry
Kelly N. Botteron, MD 1) Magnetic Resonance Imaging (MRI) studies of child and adolescent affective and attentional disorders; 2) MRI of very early brain development in infants at risk for autism; 3) MRI studies of normal brain development; 4) imaging studies in twin populations; 5) genetics of brain structure and structural correlates of neuropsychiatric disorder; 6) development/implementation of image analysis methods for neuromorphometric analysis of MRI
Kathleen Keenan Bucholz, PhD 1) PI on a longitudinal family study of alcoholism, with an over sample of African American families, to investigate 3 major developmental models of alcoholism and determine their applicability to AA families (MOFAM); 2) PI on a project studying adolescent and young adult offspring of twin fathers with and without drug/alcohol problems, to investigate genetic and environmental influences on offspring development of drug use/problems, and other psychopathology; 3) Co-Director of the continuing data collection from adolescents and young adults in a multi-site family study of alcohol dependence (COGA), with extensive phenotypic, neurophysiological and neuropsychological assessments, and genetic (including GWAS) data to uncover genetic underpinnings of alcoholism, developmental trajectories of substance involvment, and gxe interactions; 4) Co-Director of the Alcoholism Research Center, with a current focus on maternal alcoholism and its precursors, course and consequences, particularly for children. ; 5) Co-investigator on studies collecting longitudinal data on psychopathology (with an emphasis on alcoholism) in adolescent and young adult female twin samples ascertained from birth records in Missouri, adult Australian twins, their spouses, and their offspring; 6) 11 year follow up study of 753 participants in the St. Louis ECA who were at high risk of alcohol dependence when interviewed, with additional risk and protective factors obtained at re-interview; 7) 14 year follow up of 444 participants in the St. Louis ECA, to obtain information about their use and costs of health services, using both self-report (interview) and abstracted medical data
Robert M. Carney, PhD 1) the significance of psychiatric and psychosocial factors in patients with heart disease; 2) cognitive-behavioral treatment of anxiety and affective disorders; 3) psychiatric comorbidity in medical patients
Li-Shiun Chen, MD 1) Our research suggests that a person's genetic makeup can help us better predict who is most likely to respond to drug therapy so we can make sure patients are matched with optimal medication treatments. We are conducting a genetically informed smoking cessation trial to examine the use of genetic markers in identifying medications with maximal efficacy and minimal side effects, ; 2) In order to understand the natural history and public health impact of smoking, we have an ongoing longitudinal follow up study of smoking cessation in the general population.; 3) We lead an international collaborative of research on genetic markers, lung cancer, and smoking cessation success. We are interested in identifying the potential value of genetic markers in helping to identify individuals early on and reduce their risk for tobacco addiction and its related negative health consequences.; 4) We research smoking cessation in different high risk populations such as patients with severe mental illness or patients with acute myocardial infarction.
Vesselin Chorbov, PhD 1) studies of genes and gene-by-environment; 2) epigenetic interdisciplinary traslational research; 3) Analyses of region-specific & genome-wide DNA methylation microarrays
Theodore Cicero, PhD 1) gender differences in the actions and abuse liability of substances of abuse, particularly morphine and cocaine; 2) basic investigations of the role of endogenous opioid peptides in neuroendocrinology
Robert Cloninger, MD, PhD 1) well-being; 2) psychobiology of personality & psychopathology; 3) nosology of psychiatric disorders; 4) genetic epidemiology of psychiatric disorders
John Constantino, MD 1) Cerebrospinal Fluid Monoamine Metabolites as Biomarkers of Inherited Liability to Antisocial Behavior; 2) The Quantitative Nature of Autistic Traits; 3) Validation and Dissemination of the Social Responsiveness Scale; 4) Social Attachment, Psychopathology, and the Prevention of Child Maltreatment; 5) The Genetic Structure of Autism and Related Disorders
Charles Conway, MD 1) treatment resistant depression; 2) neuroimaging of mood disorders<br>new treatments for treatment resistant mood disorders; 3) bipolar disorders
Carlos Cruchaga, PhD 1) Identifying rare variants that increase risk for Alzheimer’s disease; 2) Identification of common and rare variants associated with Parkinson's disease; 3) Identification and functional characterization of the genetic variant causing Kufs’ disease with early dementia in a family with an autosomal dominant inheritance; 4) Identification of genetic variants associated with cerebrospinal fluid granulin levels; 5) Genetic architecture of stroke outcomes
Nuri Farber, MD 1) pharmacological, neuroanatomical, histochemical, and cognitive/behavioral evaluation of neurodegeneration; 2) Treatment Resistant Depression; 3) developmental disorders; 4) neurostimulation; 5) glutamate, GABA receptors; 6) glucocorticoids; 7) psychotic disorders
Kenneth Freedland, PhD 1) psychiatric comorbidity in coronary heart disease and heart failure; 2) cognitive-behavioral treatment of depression, stress, and anxiety; 3) RCT methodology for behavioral intervention research
Anne Glowinski, MD, MPE 1) Genetic epidemiology of adolescent depression & suicidality; 2) Parental alcoholism or depression as models of high risk g-e interplay; 3) Medical education; 4) Improvement of community systems of care for youth psychopathology treatment and prevention; 5) Youth at high risk for familial Bipolar Disorder; 6) Developmental Study of Toddler Twins
Richard Grucza, PhD, MPE 1) Epidemiology of alcohol, nicotine, and other drug dependence. ; 2) Alcohol and Tobacco Policy as environmental influences on substance abuse and health; 3) Human molecular genetics of addiction; 4) Health consequences of heavy drinking
Michael Harms, PhD 1) Advanced structural, functional, and diffusion MR acquisitions and analyses to study brain networks in healthy individuals and those with psychiatric conditions; 2) Endophenotypes (biological markers) of schizophrenia and psychosis; 3) Quality control of MR data, including multi-site studies; 4) Temporal dynamics of the fMRI response
Sarah Hartz, MD, PhD 1) Psychiatric Genetics; 2) Return of Genetic Results; 3) Comorbidity between substance use and severe mental illness
Andrew Heath, DPhil 1) alcoholism etiology and consequences; 2) genetic studies of alcoholism, smoking, and drug dependence; 3) genetic studies of depression, suicidality and anxiety disorders; 4) genetic studies of personality and personality disorder; 5) methodological research in genetic epidemiology; 6) genetic studies of child and adolescent psychopathology
Tamara Hershey, PhD 1) neural underpinnings of cognitive dysfunction in diseases relevant to dopamine and the basal ganglia; 2) effects of metabolic dysfunction on the brain and cognitive function
Barry Hong, PhD, ABPP 1) psychological and psychiatric aspects of chronic illness in particular renal failure, liver disease; 2) behavior effecting organ donation; 3) disaster research and training; 4) follow-up studies of living donors; 5) functional pain in IBS and chronic bladder pain
Yukitoshi Izumi, MD, PhD 1) Hippocampal synaptic plasticity and metaplasticity.; 2) Energy metabolism in the hippocampus. ; 3) Excitotoxicity in the retina and experimental retinopathology. ; 4) Pharmacological modulation of hippocampal function. ; 5) Ethanol intoxication and neurosteroids.
Michael Jarvis, MD, PhD 1) maintenance electroconvulsive therapy; 2) psychopharmacology; 3) emergency and inpatient psychiatry; 4) psychiatric education; 5) suicide
Sara L. Kornfield, PhD 1) Low-income minority women are more likely than other groups to experience traumatic stress and its associated mental health sequelae. Posttraumatic stress disorder (PTSD) symptoms are even more prevalent during pregnancy and can lead to functional impairment, poor health behaviors, and adverse pregnancy outcomes. Dr Kornfield is now studying arousal regulation via the acoustic startle paradigm in three groups of pregnant women;those with PTSD symptoms (full and partial), those with trauma exposure and no symptoms, and healthy controls. Additionally, Dr. Kornfield is testing the application of a brief primary-care based psychotherapeutic treatment aimed at relieving symptoms of partial and full PTSD.
Eric Lenze, MD 1) Incomplete Response in Late-Life Depression: Getting to Remission; 2) Mindfulness-Based Stress Reduction and Cognitive Function in Stress and Aging; 3) Enhanced Medical Rehabilitation for Older Adults; 4) Bioequivalence and Clinical Implications of Generic Bupropion; 5) Buprenorphine for Treatment Resistant Late-Life Depression; 6) Exercise and MBSR for Cognitive Function; 7) Pharmacogenetics of Anti Depressants in Older Adults
Collins Lewis, MD 1) alcoholism and comorbid disorders; 2) Vietnam veterans with PTSD
Joan Luby, MD 1) Preschool mood disorders; 2) Infant/preschool psychopathology and nosology; 3) Social/emotional development of the infant and toddler; 4) Treatment of childhood affective disorders; 5) Brain development in early onset depression
Patrick Lustman, PhD 1) examination of the interaction of mental and physical illness, including studies of the prevalence, course, and treatment of psychiatric illness in patients with diabetes mellitus and/or gastrointestinal disorders
Pamela Madden, PhD 1) genetic studies on nicotine use and dependence; 2) the relationship between genetic influences on smoking behavior, and genetic factors responsible for the use and dependence on other substances (using alcohol as a model system); 3) genetic studies of possible mediators of genetic influence on cigarette use and the development of dependence on nicotine and other substances
Daniel Mamah, MD, MPE 1) Functional Connectivity MRI in Schizophrenia, Bipolar Disorder, and High Risk States; 2) Diffusion Imaging and Neuromorphometry ; 3) Assessment of Bipolar and Psychosis Risk in the U.S., Kenya and Rwanda; 4) Cognitive Training in High Risk Youth
Vivia McCutcheon, PhD 1) alcohol use disorders, remission and relapse
Steven Mennerick, PhD 1) physiology of glutamate and GABA signaling; 2) axonal physiology; 3) synaptic modulation
Elliot Nelson, MD 1) twin study of social phobia; 2) genetic epidemiology of childhood abuse; 3) case-control candidate gene study of opioid dependence
Ginger Nicol, MD 1) cardiometabolic risk in mentally ill children; 2) psychopharmacology
Bruce Nock, PhD 1) transgenerational effects of morphine
Rumi Kato Price, PhD, MPE 1) Long-term effects of early trauma, substance abuse, posttraumatic stress disorder; 2) Deployment and reintegration mental health and substance abuse prevention in military members and veterans; 3) Health disparity relating to substance abuse and comorbid psychiatric problems; 4) Mobile and wearable technology for prevention and intervention of posttraumatic stress disorder syndrome and anxiety triggers.
John Pruett, Jr., MD, PhD 1) Functional connectivity MRI (fcMRI) studies of autism; 2) The development of visual attention to social and non-social stimuli in autistic and non-autistic individuals; 3) Visual form processing, as related to social perception and cognition; 4) Comparative cognition of reasoning and social functioning
Angela Reiersen, MD 1) Autistic Traits and Motor Problems in Children with ADHD: I have been working on a project investigating autistic traits and motor problems in a population-based twin sample enriched for ADHD.
John Rice, PhD 1) method development in genetic epidemiology; 2) quantitative genetics; 3) genetics of affective disorders; 4) linkage analysis; 5) diagnostic stability/validity; 6) analysis of multivariate data, especially survival and logistic analyses; 7) analysis of whole genome association data
John Rohrbaugh, PhD 1) brain electrical and psychophysiological studies of attention and cognition in normal subjects and in psychiatric patients; 2) novel methods for assessing emotion, stress and credibility
Eugene Rubin, MD, PhD 1) Depression and co-morbid medical illnesses; 2) Dementia; 3) Trends in psychiatric education
Chad Sylvester, MD, PhD 1) Functional brain networks are groups of brain regions that work together to carry out particular functions, such as cognitive control or self-reflection. Dr. Sylvester uses computer games and functional magnetic resonance imaging (fMRI) to study alterations in functional brain networks associated with pediatric anxiety disorders. A long term goal is to develop new treatments (using, for example, computer games) that directly target alterations in functional brain networks.
Mini Tandon, DO 1) childhood ADHD and disruptive disorders; 2) characterization of disorders in preschool period; 3) empirically-supported psychotherapies for preschoolers
Alexandre Todorov, PhD 1) Psychiatric genetics; 2) Study design and methods for genetic; 3) epidemiological studies
Dorothy Van Buren, PhD 1) lifestyle interventions for youth with Type 2 diabetes and their families; 2) psychological treatments for binge eating disorder; 3) family based, behavioral treatments for pediatric obesity; 4) behavioral family therapy with adolescents with anorexia nervosa; 5) dissemination of evidence based treatments into community practice settings
Denise Wilfley, PhD 1) causes, characterization, and treatment of obesity and eating disorders; 2) assessment and psychological treatments for eating disorders and obesity; 3) prevention of eating disorders and obesity in at-risk populations; 4) maintenance treatments for childhood obesity; 5) behavioral lifestyle intervention for obese children and their parents; 6) family-based and pharmacological interventions applied to the treatment of anorexia nervosa
David Wozniak, PhD 1) the role of excitatory amino acids in aging and development, Alzheimer;s disease, schizophrenia and other neuropsychiatric disorders; 2) the involvement of glutamate receptors in learning and memory, and neuronal injury and degeneration; 3) rodent models of developmental neuropsychiatric syndromes such as the fetal alcohol syndrome and Neurofibromatosis - Type 1; 4) behavioral phenotyping of mutant mice and the development of rodent models of human diseases
Charles Zorumski, MD 1) mechanisms regulating the actions of glutamate and GABA in the hippocampus; 2) short- and long-term synaptic plasticity in the hippocampus; 3) mechanisms involved in CNS neurodegeneration